TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05362318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch and lozenges
Description: Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch and lozenges
Description: Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling sessions
Description: Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to a web-based video
Description: Participants will be given web-based access to the relapse prevention video Surviving Smokefree.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Florida Tobacco Quitline
Description: Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Florida Tobacco Quitline
Description: Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
Study: NCT06170918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: remimazolam is given intravenously
Study: NCT05426278

Intervention type: DEVICE
Group type: OTHER
Intervention: Bair hugger and Forces air warmer
Description: The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
Study: NCT05219058

Intervention type: PROCEDURE
Intervention: Biological mesh reconstruction
Description: Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.

Intervention type: PROCEDURE
Intervention: Biological mesh reconstruction
Description: Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.

Intervention type: PROCEDURE
Intervention: Myocutaneous flap reconstruction
Description: Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.

Intervention type: PROCEDURE
Intervention: Myocutaneous flap reconstruction
Description: Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.

Intervention type: PROCEDURE
Intervention: Primary closure reconstruction
Description: Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.

Intervention type: PROCEDURE
Intervention: Primary closure reconstruction
Description: Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
Study: NCT06490042

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire about helmet use and attitude towards helmet use.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire about helmet use and attitude towards helmet use.
Study: NCT06224569

Intervention type: OTHER
Group type: OTHER
Intervention: Black tea flavoured, tea drink
Description: Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.

Intervention type: OTHER
Group type: OTHER
Intervention: Black tea flavoured, caffeine-only drink
Description: 50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Black tea flavoured, placebo drink
Description: A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.

Intervention type: OTHER
Group type: OTHER
Intervention: Green tea flavoured, tea drink
Description: Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.

Intervention type: OTHER
Group type: OTHER
Intervention: Green tea flavoured, caffeine-only drink
Description: 30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Green tea flavoured, placebo drink
Description: A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
Study: NCT05940584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-Reha provided with EvoPads
Description: Exercises and cognitive training provided on an EvoPad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based exercises with option to do tele-reha afterwards
Description: Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only paper-based exercises
Description: Same exercises and cognitive training as Group 2 provided on paper only.
Study: NCT06196463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinale block (ESP block)
Description: The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AG + sham block
Description: General anesthesia
Study: NCT05626751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZN-825
Description: HZN-825 will be administered BID for 52 weeks
Study: NCT04943965

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC
Study: NCT04964453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
Study: NCT04656210

Intervention type: RADIATION
Intervention: MRI
Description: Non conventional MRI (35 minutes)

Intervention type: RADIATION
Intervention: MRI
Description: Non conventional MRI (35 minutes)

Intervention type: OTHER
Intervention: neuropsychological tests
Description: Standardized and quantified neuropsychological assessment

Intervention type: OTHER
Intervention: neuropsychological tests
Description: Standardized and quantified neuropsychological assessment
Study: NCT06095466

Intervention type: DEVICE
Intervention: Echocardiographic assessment
Description: M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Immunohistochemistry
Description: In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide.
Study: NCT04138875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
Study: NCT05862064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
Description: Conventional chemotherapy in combination with carrelizumab

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: epirubicin,cyclophosphamide,paclitaxel
Description: Conventional chemotherapy
Study: NCT06227507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
Study: NCT06421376

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy ±immunotherapy
Description: Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
Study: NCT05835180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 - 50 mg
Description: TVB-2640 -50 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 - 50 mg
Description: TVB-2640 -50 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 - 50 mg
Description: TVB-2640 -50 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 - 50 mg
Description: TVB-2640 -50 mg administered orally once daily
Study: NCT04820413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Description: FMT by daily enema with donor faeces
Study: NCT05611021

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three conditions will be tested: Walking, arm-cranking and control condition.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Three conditions will be tested: Walking, arm-cranking and control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Three conditions will be tested: Walking, arm-cranking and control condition.
Study: NCT06335316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive therapy
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
Study: NCT05760768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized exercise guidance
Description: Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
Study: NCT04993443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQ036
Description: For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo for LQ036: Matching Placebo
Study: NCT04579159

Intervention type: DEVICE
Group type: OTHER
Intervention: Preventicus heartbeat app in combination with wearables
Description: CE certified devices
Study: NCT06076174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-week home-based exercise programme
Description: All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise programme
Description: All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
Study: NCT05656729

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DefensePlus
Description: Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
Study: NCT05146193

Intervention type: OTHER
Intervention: Nude back photo
Description: Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
Study: NCT06481215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-068
Description: The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara®
Description: The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
Study: NCT05216302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Nordic Walking Exercise Program
Description: An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
Study: NCT04808141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital program
Description: Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.